Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Let evidence be the arbiter.

Mary Catherine Lindberg1

  • 1Ontario Council of Teaching Hospitals.

Healthcarepapers
|June 18, 2003
PubMed
Summary
This summary is machine-generated.

Ensuring drug programs offer value for money requires evidence-based decision-making. A new strategy proposes using data to guide affordable drug access, benefiting patients and healthcare systems.

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same journal

Building the Structures and Ecosystem Required for Sustainable Health Innovation in Canada.

HealthcarePapers·2026
Same journal

Is Health Canada the Key to Cracking the Nut of Healthcare Reform?

HealthcarePapers·2026
Same journal

Rethinking the Federal Role in Health: Revisiting the 2015 Naylor Report on Healthcare Innovation.

HealthcarePapers·2026
Same journal

Scaling Innovation in a Publicly Funded System: A UK Pathway From Evidence to Adoption.

HealthcarePapers·2026
Same journal

Accelerating Innovation and Technological Transformation on a National Scale.

HealthcarePapers·2026
Same journal

Beyond Silos and Perpetual Pilots: Data as the Catalyst for Canada's Healthcare Innovation Revolution.

HealthcarePapers·2026

Area of Science:

  • Health Economics
  • Pharmaceutical Policy
  • Evidence-Based Medicine

Background:

  • Long-standing debate on cost-effectiveness in drug evaluation.
  • Previous strategies include formularies, restricted listings, and price negotiations.
  • Need for a transparent and universally understood drug assessment method.

Discussion:

  • Proposed strategy emphasizes evidence as the primary determinant for drug value.
  • Advocates for a unified approach to drug evaluation accessible to all stakeholders.
  • Highlights the necessity of courage from all parties to adopt new methods.

Key Insights:

  • Evidence-based drug evaluation ensures value for money spent.
  • A transparent system promotes understanding among all involved parties.
  • Affordable drug programs can be maintained without compromising patient health outcomes.

Outlook:

  • Potential for improved drug program affordability through evidence-based strategies.
  • Opportunity to foster collaboration among pharmaceutical manufacturers, payers, and policymakers.
  • Facilitating access to essential treatments while managing healthcare costs effectively.